Decreased butyrylcholinesterase and oxytocin levels versus increased dopamine levels in advanced Alzheimer's patients

Authors

  • Durmus Ayan Omer Halisdemir University, Research and Training Hospital, Department of Medical Biochemistry, Nigde, Türkiye
  • Esma Ozmen Omer Halisdemir University, Faculty of Medicine, Department of Medical Biochemistry, Nigde, Türkiye
  • Serpil Ersan Omer Halisdemir University, Faculty of Medicine, Department of Medical Biochemistry, Nigde, Türkiye
  • Ismail Sari Omer Halisdemir University, Faculty of Medicine, Department of Medical Biochemistry, Nigde, Türkiye
  • Etem Erdal Ersan Omer Halisdemir University, Faculty of Medicine, Department of Psychiatry, Nigde, Türkiye
  • Sibel Soylemez Gazi University, Facutly of Medicine, Department of Medical Biochemistry, Ankara, Türkiye

Keywords:

Alzheimer, Dopamine, Oxytocin, Butyrylcholinesterase

Abstract

Aim: In this study, it was aimed to examine the serum levels of dopamine, oxytocin, and butyrylcholinesterase (BchE) enzyme activity in advanced Alzheimer's disease (AD).

Materials and Methods: For our preliminary study, a total of 40 participants were included in the study. 20 of the participants consisted of patients and the other 20 made up the control group. In the serum samples of the patient and control group, the levels of dopamine and oxytocin were measured by Enzyme-Linked Immuno Sorbent Assay (ELISA) method, while the BchE activity was measured by the spectrophotometric method.

Results: We found that serum BchE and oxytocin levels in the AD group were statistically lower than the controls (p<0.01, p=0.027), whereas serum dopamine levels in the AD group were statistically higher than the control group (p=0.02). Furthermore, we analyzed that there was no significant correlation between the measured parameters (p>0.05).

Conclusion: Our results indicate that the decrease in BchE activity and oxytocin levels and the increase in dopamine levels may have a relationship with the progression of the disease in the AD group. However, we believe that studies are needed with larger numbers of patients with different levels of AD.

Downloads

Download data is not yet available.

Downloads

Published

2022-08-26

Issue

Vol. 29 No. 8 (2022): August

Section

Original Articles

License

Copyright (c) 2022 Annals of Medical Research

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

CC Attribution-NonCommercial-NoDerivatives 4.0

How to Cite

1.
Decreased butyrylcholinesterase and oxytocin levels versus increased dopamine levels in advanced Alzheimer’s patients. Ann Med Res [Internet]. 2022 Aug. 26 [cited 2025 Apr. 4];29(8):864-8. Available from: http://annalsmedres.org/index.php/aomr/article/view/4240